Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Fasenra has received EU approval for treating eosinophilic granulomatosis with polyangiitis
Latest Hotspot
3 min read
Fasenra has received EU approval for treating eosinophilic granulomatosis with polyangiitis
30 October 2024
AstraZeneca’s Fasenra (benralizumab) has received approval in the EU as a supplementary therapy for adults dealing with relapsing or refractory eosinophilic granulomatosis with polyangiitis.
Read →
Barzolvolimab Meets Primary and Secondary Endpoints in Phase 2 Trial for Chronic Inducible Urticaria
Latest Hotspot
3 min read
Barzolvolimab Meets Primary and Secondary Endpoints in Phase 2 Trial for Chronic Inducible Urticaria
30 October 2024
Celldex Reports Barzolvolimab Successfully Achieved All Main and Secondary Goals with Strong Statistical Significance in Positive Phase 2 Trial for Chronic Inducible Urticaria.
Read →
Biogen Presents Positive Phase 2 Results for Felzartamab in IgA Nephropathy at ASN Kidney Week 2024
Latest Hotspot
3 min read
Biogen Presents Positive Phase 2 Results for Felzartamab in IgA Nephropathy at ASN Kidney Week 2024
30 October 2024
Biogen shares promising findings from the Phase 2 IGNAZ trial of Felzartamab for IgA nephropathy during Kidney Week 2024 hosted by the American Society of Nephrology (ASN).
Read →
Zymeworks Showcases Latest ADC Preclinical Data at EORTC-NCI-AACR Conference
Latest Hotspot
4 min read
Zymeworks Showcases Latest ADC Preclinical Data at EORTC-NCI-AACR Conference
29 October 2024
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference.
Read →
Exploring Growth and Innovation within the Global Antisense Oligonucleotide Therapeutics Market
Hot Spotlight
10 min read
Exploring Growth and Innovation within the Global Antisense Oligonucleotide Therapeutics Market
29 October 2024
As a cutting-edge therapeutic approach, antisense oligonucleotide drugs precisely target the mRNA or pre-mRNA of disease-causing genes.
Read →
Jubilant Therapeutics Begins Global Trials for Cancer Drugs JBI-802 and JBI-778
Latest Hotspot
3 min read
Jubilant Therapeutics Begins Global Trials for Cancer Drugs JBI-802 and JBI-778
29 October 2024
Jubilant Therapeutics Inc. has reported the initial dosing of patients in worldwide clinical trials for JBI-802, a CoREST inhibitor, and JBI-778, a PRMT5 inhibitor.
Read →
Targeting the Source of IgA Nephropathy: World’s First APRIL Antibody Shows Positive Phase III Results
Hot Spotlight
5 min read
Targeting the Source of IgA Nephropathy: World’s First APRIL Antibody Shows Positive Phase III Results
29 October 2024
Otsuka Pharmaceutical announced positive top-line interim data from the phase III clinical trial of sibeprenlimab for treating adults with IgA nephropathy.
Read →
Maze Therapeutics Reports Positive Phase 1 Results for MZE829 in Treating APOL1 Kidney Disease
Latest Hotspot
4 min read
Maze Therapeutics Reports Positive Phase 1 Results for MZE829 in Treating APOL1 Kidney Disease
29 October 2024
Maze Therapeutics announces encouraging initial human data from a Phase 1 trial involving healthy participants.
Read →
Hope Medicine's "World's First" PRLR Monoclonal Antibody Announces Latest Phase 2 Clinical Progress
Hot Spotlight
4 min read
Hope Medicine's "World's First" PRLR Monoclonal Antibody Announces Latest Phase 2 Clinical Progress
29 October 2024
Hope Medicine (HopeMed) announced positive interim results from a Phase 2 study of HMI-115 in women with moderate to severe endometriosis-associated pain.
Read →
Kymera Therapeutics Starts Phase 1 Trial of KT-621 with First Participant Dosed
Latest Hotspot
3 min read
Kymera Therapeutics Starts Phase 1 Trial of KT-621 with First Participant Dosed
29 October 2024
Kymera Therapeutics has begun administering doses to the initial participant in its Phase 1 clinical trial of KT-621.
Read →
Tonix Pharmaceuticals Submits NDA for TNX-102 SL, Offering New Hope for Fibromyalgia Patients
Hot Spotlight
3 min read
Tonix Pharmaceuticals Submits NDA for TNX-102 SL, Offering New Hope for Fibromyalgia Patients
29 October 2024
Tonix Pharmaceuticals announced that it has submitted a New Drug Application (NDA) to the U.S. FDA for TNX-102 SL (Cyclobenzaprine hydrochloride).
Read →
Intellia Reports Positive Phase 2 Results for CRISPR Therapy NTLA-2002 in HAE Treatment
Latest Hotspot
5 min read
Intellia Reports Positive Phase 2 Results for CRISPR Therapy NTLA-2002 in HAE Treatment
29 October 2024
Intellia Announces Encouraging Outcomes from Phase 2 Trial of NTLA-2002, a CRISPR Gene Editing Therapy for Hereditary Angioedema (HAE).
Read →